Home ยป OLN324 Shows Greater Retinal Drying vs Faricimab in DME: JADE Trial

OLN324 Shows Greater Retinal Drying vs Faricimab in DME: JADE Trial

by Team SunilMadhavs World

OLN324 Shows Encouraging Anatomic Efficacy and Safety vs Faricimab in DME and Wet AMD: JADE Trial

1-Minute Summary

The investigational VEGF/angiopoietin-2 bispecific antibody OLN324 demonstrated encouraging anatomic activity, visual outcomes, durability, and ocular safety in the randomized phase 1b JADE proof-of-concept trial involving patients with diabetic macular edema (DME) or neovascular age-related macular degeneration (nAMD).

JADE enrolled 164 adults and compared intravitreal OLN324 at doses of 2 mg or 4 mg with faricimab 6 mg.

Patients initially received monthly treatment, with the primary efficacy assessment performed at week 12 and final follow-up extending through week 20.

Among patients with DME, OLN324 produced faster and greater reductions in central subfield thickness than faricimab. At week 12, mean central subfield thickness decreased by approximately 180 ยตm with OLN324 4 mg compared with 121 ยตm with faricimab.

Nearly 90% of DME patients receiving OLN324 4 mg achieved absence of DME at week 12, compared with 57% receiving faricimab.

In nAMD, overall retinal drying was broadly similar between therapies, but OLN324 produced more pronounced reductions in pigment epithelial detachment and numerically greater gains in best-corrected visual acuity.

At week 20, mean visual acuity gains in nAMD were approximately +8.6 letters with OLN324 4 mg compared with +6.4 letters with faricimab, a numerical difference of 2.2 letters.

OLN324 also showed an encouraging ocular safety profile. No cases of intraocular inflammation, retinal vasculitis, occlusive retinal vasculitis, or endophthalmitis were reported among OLN324-treated participants during the 20-week trial.

The findings support continued phase 3 development but should be interpreted cautiously because JADE was an early-phase proof-of-concept study rather than a definitive comparative efficacy trial.


Why This Matters

Antiโ€“vascular endothelial growth factor therapy has transformed the treatment of retinal vascular diseases such as diabetic macular edema and neovascular age-related macular degeneration.

However, important clinical challenges remain.

Some patients have persistent intraretinal or subretinal fluid despite repeated injections, while others experience recurrent disease when treatment intervals are extended.

Treatment burden is another major concern because many patients require repeated intravitreal injections over years.

OLN324 was designed as a next-generation bispecific antibody targeting both:

  • vascular endothelial growth factor A (VEGF-A), and
  • angiopoietin-2 (Ang2).

This dual mechanism is similar conceptually to faricimab, which also targets VEGF-A and Ang2, but OLN324 has been engineered differently.

The investigational molecule has a smaller molecular format of approximately 41 kDa, higher binding affinity for Ang2, and greater molar exposure per injection.

Investigators hypothesize that these characteristics may improve penetration within retinal tissues and provide greater suppression of vascular leakage.

The JADE trial therefore asked an important question: could a more potent and smaller VEGF/Ang2 bispecific antibody improve retinal anatomy or treatment durability relative to an established dual-pathway therapy?


Study at a Glance

Feature Details
Study JADE
Study type Randomized, masked, active-comparator phase 1b proof-of-concept clinical trial
ClinicalTrials.gov NCT07484074
Participants 164
Conditions Diabetic macular edema and neovascular/wet AMD
DME population Treatment-naive or previously treated
nAMD population Treatment-naive
Intervention 1 Intravitreal OLN324 2 mg
Intervention 2 Intravitreal OLN324 4 mg
Comparator Intravitreal faricimab 6 mg
Mechanism Dual VEGF/Ang2 inhibition
Initial dosing Monthly loading doses
Primary efficacy assessment Week 12
Final study visit Week 20
Key efficacy measures Central subfield thickness, disease resolution, BCVA, pigment epithelial detachment
Primary early finding Greater retinal drying in DME with OLN324; comparable CST drying with additional anatomic signals in nAMD
Key safety finding No intraocular inflammation reported with OLN324
Sponsor Ollin Biosciences

JADE was registered as a randomized, parallel-assignment, masked phase 1b study of OLN324 and faricimab in DME and nAMD.


What the Researchers Found

Faster Retinal Drying in Diabetic Macular Edema

One of the strongest efficacy signals emerged in patients with DME.

Changes in central subfield thickness, measured by optical coherence tomography, began to separate between treatment groups soon after therapy.

At week 1, mean central subfield thickness decreased by approximately:

DME OCT outcome OLN324 4 mg Faricimab
Mean CST change at week 1 โˆ’79 ยตm โˆ’45 ยตm

The reduction with OLN324 was therefore approximately 75% greater at this early time point.

By week 12:

DME OCT outcome OLN324 4 mg Faricimab
Mean CST change โˆ’180 ยตm โˆ’121 ยตm

The difference represented approximately 50% greater retinal drying with OLN324 4 mg based on these mean changes.

The rapid separation beginning at week 1 suggests that OLN324 may exert potent early suppression of retinal vascular leakage.


Nearly 90% Achieved DME Resolution

An additional anatomic endpoint assessed the proportion of patients who no longer met the studyโ€™s OCT definition of diabetic macular edema.

At week 12:

DME resolution OLN324 4 mg Faricimab
Absence of DME Nearly 90% 57%

Absence of DME was defined using a central subfield thickness threshold of less than 325 ยตm.

This represents one of the most notable findings from the early JADE dataset.

However, the analysis was performed in a relatively small phase 1b population, and phase 3 trials are necessary before concluding that OLN324 provides superior disease control.


Visual Acuity in DME

Despite greater anatomic drying, visual acuity outcomes were relatively similar across treatments.

At week 20:

Treatment Mean BCVA gain
OLN324 2 mg +7.4 letters
OLN324 4 mg +8.1 letters
Faricimab 6 mg +7.7 letters

Thus, the greater reduction in retinal thickness did not translate into a clearly established visual-acuity advantage during the short follow-up period.

This distinction is clinically important.

Improved anatomy may be desirable, but the ultimate goal of treatment is preservation or improvement of vision. Larger trials with longer follow-up will be necessary to determine whether anatomic differences lead to clinically meaningful functional benefits.


Findings in Neovascular AMD

The nAMD cohort showed a somewhat different efficacy pattern.

Mean central subfield thickness improved rapidly with both OLN324 and faricimab and remained broadly comparable through week 20.

However, OLN324 showed potentially favorable effects on pigment epithelial detachment, an OCT feature frequently seen in neovascular AMD.

Investigators reported earlier, greater, and more durable reductions in pigment epithelial detachment thickness with OLN324 compared with faricimab.

This suggests that OLN324โ€™s higher Ang2 potency and smaller molecular structure may produce additional effects on certain components of neovascular disease even when overall retinal-fluid reduction is similar.


Visual Acuity in Wet AMD

At week 20, mean best-corrected visual-acuity gains were:

Treatment Mean BCVA gain at week 20
OLN324 2 mg +8.4 letters
OLN324 4 mg +8.6 letters
Faricimab 6 mg +6.4 letters

The OLN324 4-mg group therefore had a numerical advantage of approximately 2.2 letters compared with faricimab.

However, JADE was not designed or powered as a definitive superiority trial for visual acuity.

These values should therefore be regarded as encouraging numerical observations rather than evidence that OLN324 provides superior visual outcomes.


Pigment Epithelial Detachment

Pigment epithelial detachment may persist in some patients with neovascular AMD despite anti-VEGF therapy.

In JADE, OLN324 produced:

  • earlier flattening of pigment epithelial detachments,
  • greater reductions in PED thickness,
  • and more sustained anatomic improvement.

David Eichenbaum, MD, described the early findings as encouraging and suggested that the bispecific molecule:

โ€œmay really be a step ahead for us.โ€

This observation remains hypothesis-generating and requires confirmation in prospective phase 3 studies.


Durability and Retreatment

After the initial mandatory loading treatment, patients entered an observation period in which retreatment could occur according to predefined recurrence criteria.

DME

At week 20:

No retreatment during follow-up OLN324 4 mg Faricimab
DME patients 93% 89%

Neovascular AMD

No retreatment during follow-up OLN324 4 mg Faricimab
nAMD patients 82% 81%

These findings suggest encouraging durability but do not demonstrate a large or definitive retreatment advantage.

The numerically small differences require confirmation in larger trials designed specifically to evaluate dosing intervals and treatment burden.


Why OLN324 May Behave Differently

OLN324 and faricimab both inhibit VEGF and Ang2, but their molecular architecture differs.

OLN324 is approximately 41 kDa, substantially smaller than a conventional full-length antibody.

Potential theoretical advantages include:

  • improved retinal tissue penetration,
  • high molar concentration,
  • stronger Ang2 binding,
  • rapid target engagement,
  • and potentially stronger suppression of vascular permeability.

OLN324 has been described as having up to approximately 60-fold greater anti-Ang2 potency than faricimab in preclinical characterization.

Whether this biochemical difference translates into meaningful long-term clinical superiority remains unknown.


Safety

No Intraocular Inflammation With OLN324

Ocular inflammation is an important safety issue for intravitreal biologic therapies.

Through week 20, investigators reported:

Ocular safety event OLN324 Faricimab
Intraocular inflammation 0 1 case
Retinal vasculitis 0 0
Occlusive retinal vasculitis 0 0
Endophthalmitis 0 reported โ€”

No cases of intraocular inflammation were identified among OLN324-treated participants at either dose.

One case of mild intraocular inflammation occurred in a faricimab-treated participant.

No retinal vasculitis or occlusive retinal vasculitis occurred in the OLN324 groups.

These findings are reassuring but should be interpreted in the context of only 164 participants and 20 weeks of follow-up.

Rare inflammatory adverse effects may not become evident until substantially larger populations are exposed.


Clinical Significance

JADE provides early evidence that OLN324 is biologically active and potentially differentiated from existing VEGF/Ang2 therapy.

The strongest signal appears to be in diabetic macular edema, where OLN324 produced:

  • faster retinal drying,
  • greater mean CST reduction,
  • a higher proportion of eyes meeting the study definition of DME resolution,
  • and similar visual-acuity gains.

In neovascular AMD, overall retinal drying was similar to faricimab, but OLN324 demonstrated potentially favorable effects on pigment epithelial detachment and numerically greater visual-acuity improvement.

The safety findings are also encouraging, particularly the absence of intraocular inflammation among OLN324-treated participants.

If these signals are reproduced in phase 3 studies, OLN324 could potentially provide clinicians with another high-potency dual-pathway option for retinal vascular disease.


Limitations

1. Early-Phase Trial

JADE was a phase 1b proof-of-concept study.

Its purpose was primarily to characterize safety, tolerability, pharmacokinetics, and exploratory efficacy rather than establish definitive clinical superiority.


2. Small Sample Size

Only 164 participants were enrolled across both DME and neovascular AMD cohorts and 3 treatment groups.

Subgroup populations were therefore relatively small.


3. Short Follow-up

The final assessment occurred at week 20.

Retinal diseases such as DME and nAMD require treatment over many years.

The study cannot establish long-term:

  • durability,
  • visual outcomes,
  • injection frequency,
  • inflammation risk,
  • or rare adverse effects.

4. Anatomic Improvement Does Not Necessarily Equal Better Vision

The strongest differences in DME involved OCT anatomy.

Visual acuity gains were similar among DME treatment groups.

A clinically meaningful therapy should ideally improve vision and reduce treatment burden, not only produce a thinner retina on OCT.


5. Numerical BCVA Differences Were Exploratory

The approximately 2.2-letter advantage observed with OLN324 4 mg in nAMD was numerical.

The study was too small to establish whether this represents a reproducible visual-acuity advantage.


6. Industry-Sponsored Development Program

OLN324 is being developed by Ollin Biosciences.

Several investigators, including David Eichenbaum, reported extensive relationships with ophthalmic pharmaceutical and biotechnology companies.

Financial disclosures do not invalidate the findings but are relevant when interpreting early-phase investigational data.


7. Much of the Detailed Dataset Is Not Yet From a Peer-Reviewed Primary Manuscript

The results have been presented at scientific meetings and reported through trial registries, conference coverage, and company communications.

A full peer-reviewed publication would allow more detailed assessment of:

  • statistical methods,
  • missing data,
  • subgroup sizes,
  • prespecified vs post hoc analyses,
  • adverse events,
  • and confidence intervals.

What Doctors Should Know

JADE should currently be viewed as promising early evidence rather than practice-changing evidence.

Key clinical points include:

  • OLN324 is an investigational dual VEGF/Ang2 bispecific antibody.
  • JADE was a randomized phase 1b active-comparator trial.
  • 164 patients with DME or nAMD were enrolled.
  • OLN324 was evaluated at 2 mg and 4 mg.
  • The active comparator was faricimab 6 mg.
  • In DME, OLN324 produced faster and greater retinal drying.
  • Nearly 90% of DME patients receiving OLN324 4 mg met the study definition for absence of DME at week 12 vs 57% with faricimab.
  • DME visual-acuity gains were similar between treatments.
  • nAMD retinal drying was generally comparable.
  • OLN324 showed more favorable PED reductions in nAMD.
  • nAMD visual-acuity outcomes numerically favored OLN324 but were not definitive.
  • No intraocular inflammation occurred with OLN324 during the trial.
  • The study was too small and short to establish rare safety risks.
  • Phase 3 trials are necessary before efficacy or superiority conclusions can guide routine practice.
  • OLN324 remains investigational and is not an approved substitute for currently approved anti-VEGF therapies.

Bottom Line

The randomized phase 1b JADE trial provides encouraging proof-of-concept evidence for OLN324, a next-generation VEGF/Ang2 bispecific antibody being developed for diabetic macular edema and neovascular age-related macular degeneration.

Among patients with DME, OLN324 4 mg produced faster and greater reductions in central subfield thickness than faricimab, with mean CST decreasing approximately 180 ยตm vs 121 ยตm at week 12.

Nearly 90% of OLN324 4-mg recipients achieved absence of DME, compared with 57% receiving faricimab.

In neovascular AMD, overall retinal drying was similar, but OLN324 demonstrated potentially stronger effects on pigment epithelial detachment and numerically greater visual-acuity gains.

At week 20, mean BCVA increased approximately 8.6 letters with OLN324 4 mg compared with 6.4 letters with faricimab.

No intraocular inflammation, retinal vasculitis, occlusive retinal vasculitis, or endophthalmitis was reported among OLN324-treated participants through 20 weeks.

The results support further clinical development but do not yet establish OLN324 as superior to faricimab.

Confirmation in adequately powered phase 3 trialsโ€”with longer follow-up, clinically meaningful vision endpoints, durability assessments, and larger safety populationsโ€”is required.


Original Research / DOI

Study: JADE

Registered study title: A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

ClinicalTrials.gov identifier: NCT07484074

Study identifier: OLN324-CP-01

Study phase: Phase 1b

Enrollment: 164 participants

Sponsor: Ollin Biosciences

Conference presentation:
Eichenbaum D, et al. Results of JADE, a randomized, proof-of-concept clinical trial comparing OLN324, a higher-potency, small-format VEGF/Ang2 bispecific antibody, with faricimab in patients with diabetic macular edema or neovascular age-related macular degeneration.

Meeting: 26th EURETINA Congress

Dates: October 1-4, 2026

Location: Vienna, Austria

Primary presentation date: October 2, 2026

DOI: No peer-reviewed primary JADE manuscript with a unique DOI was identified at the time of this review.

The registered study is listed as completed and confirms 164 participants randomized among OLN324 2 mg, OLN324 4 mg, and faricimab 6 mg. The EURETINA presentation was explicitly described as the completed randomized head-to-head JADE proof-of-concept trial.

You may also like

Leave a Comment


Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?